Supernus Pharmaceuticals (NASDAQ:SUPN) SVP Sells $229,350.00 in Stock

Key Points

• Supernus Pharmaceuticals SVP Frank Mottola sold 5,000 shares of the company's stock for $229,350, reducing his ownership by 24.40% to 15,496 shares.
• The company's stock price decreased by 3.2%, closing at $43.99, while the trading volume surged to 794,454 shares.
• Analysts have recently upgraded their ratings for Supernus Pharmaceuticals, with two providing a "buy" rating and a consensus target price of $43.00.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) SVP Frank Mottola sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $45.87, for a total transaction of $229,350.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares in the company, valued at approximately $710,801.52. This trade represents a 24.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Frank Mottola also recently made the following trade(s):

• On Monday, August 25th, Frank Mottola sold 14,000 shares of Supernus Pharmaceuticals stock. The stock was sold at an average price of $44.51, for a total transaction of $623,140.00.

Supernus Pharmaceuticals Stock Down 3.2%

Shares of Supernus Pharmaceuticals stock traded down $1.47 during trading on Monday, hitting $43.99. The stock had a trading volume of 794,454 shares, compared to its average volume of 595,633. The stock has a 50 day simple moving average of $39.42 and a 200 day simple moving average of $34.62. The company has a market capitalization of $2.47 billion, a PE ratio of 17.35 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $46.78.

Institutional Trading of Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Osaic Holdings Inc. lifted its stake in shares of Supernus Pharmaceuticals by 211.5% in the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company's stock worth $63,000 after buying an additional 1,328 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Supernus Pharmaceuticals by 9.8% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 21,245 shares of the specialty pharmaceutical company's stock valued at $670,000 after buying an additional 1,893 shares during the period. Squarepoint Ops LLC increased its holdings in Supernus Pharmaceuticals by 63.8% in the 2nd quarter. Squarepoint Ops LLC now owns 119,978 shares of the specialty pharmaceutical company's stock valued at $3,782,000 after buying an additional 46,711 shares during the period. Thrivent Financial for Lutherans grew its holdings in shares of Supernus Pharmaceuticals by 1.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 41,170 shares of the specialty pharmaceutical company's stock worth $1,298,000 after purchasing an additional 611 shares during the last quarter. Finally, Ashford Capital Management Inc. grew its holdings in shares of Supernus Pharmaceuticals by 1.4% in the 2nd quarter. Ashford Capital Management Inc. now owns 574,372 shares of the specialty pharmaceutical company's stock worth $18,104,000 after purchasing an additional 7,816 shares during the last quarter.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Cantor Fitzgerald lifted their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Finally, Piper Sandler lifted their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research note on Friday, August 29th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Supernus Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $43.00.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.